192 related articles for article (PubMed ID: 30872730)
1. Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator.
Oh BY; Shin HT; Yun JW; Kim KT; Kim J; Bae JS; Cho YB; Lee WY; Yun SH; Park YA; Park YH; Im YH; Lee J; Joung JG; Kim HC; Park WY
Sci Rep; 2019 Mar; 9(1):4542. PubMed ID: 30872730
[TBL] [Abstract][Full Text] [Related]
2. Deciphering intratumor heterogeneity using cancer genome analysis.
Ryu D; Joung JG; Kim NK; Kim KT; Park WY
Hum Genet; 2016 Jun; 135(6):635-42. PubMed ID: 27126234
[TBL] [Abstract][Full Text] [Related]
3. Multiregion ultra-deep sequencing reveals early intermixing and variable levels of intratumoral heterogeneity in colorectal cancer.
Suzuki Y; Ng SB; Chua C; Leow WQ; Chng J; Liu SY; Ramnarayanan K; Gan A; Ho DL; Ten R; Su Y; Lezhava A; Lai JH; Koh D; Lim KH; Tan P; Rozen SG; Tan IB
Mol Oncol; 2017 Feb; 11(2):124-139. PubMed ID: 28145097
[TBL] [Abstract][Full Text] [Related]
4. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer.
Mao X; Zhang Z; Zheng X; Xie F; Duan F; Jiang L; Chuai S; Han-Zhang H; Han B; Sun J
J Thorac Oncol; 2017 Apr; 12(4):663-672. PubMed ID: 28007624
[TBL] [Abstract][Full Text] [Related]
5. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G
Cells; 2019 Jun; 8(6):. PubMed ID: 31197119
[TBL] [Abstract][Full Text] [Related]
6. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
[TBL] [Abstract][Full Text] [Related]
7. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival.
Morris LG; Riaz N; Desrichard A; Şenbabaoğlu Y; Hakimi AA; Makarov V; Reis-Filho JS; Chan TA
Oncotarget; 2016 Mar; 7(9):10051-63. PubMed ID: 26840267
[TBL] [Abstract][Full Text] [Related]
8. Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.
Yang M; Topaloglu U; Petty WJ; Pagni M; Foley KL; Grant SC; Robinson M; Bitting RL; Thomas A; Alistar AT; Desnoyers RJ; Goodman M; Albright C; Porosnicu M; Vatca M; Qasem SA; DeYoung B; Kytola V; Nykter M; Chen K; Levine EA; Staren ED; D'Agostino RB; Petro RM; Blackstock W; Powell BL; Abraham E; Pasche B; Zhang W
J Hematol Oncol; 2017 May; 10(1):100. PubMed ID: 28472989
[TBL] [Abstract][Full Text] [Related]
9. Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma.
Kim EY; Cho EN; Park HS; Kim A; Hong JY; Lim S; Youn JP; Hwang SY; Chang YS
BMC Cancer; 2016 Jan; 16():27. PubMed ID: 26782967
[TBL] [Abstract][Full Text] [Related]
10. Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project.
Lee Y; Lee S; Sung JS; Chung HJ; Lim AR; Kim JW; Choi YJ; Park KH; Kim YH
Cancer Res Treat; 2021 Jan; 53(1):123-130. PubMed ID: 32810930
[TBL] [Abstract][Full Text] [Related]
11. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
12. Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients.
Wong SQ; Fellowes A; Doig K; Ellul J; Bosma TJ; Irwin D; Vedururu R; Tan AY; Weiss J; Chan KS; Lucas M; Thomas DM; Dobrovic A; Parisot JP; Fox SB
Br J Cancer; 2015 Apr; 112(8):1411-20. PubMed ID: 25742471
[TBL] [Abstract][Full Text] [Related]
13. The challenges of tumor genetic diversity.
Mroz EA; Rocco JW
Cancer; 2017 May; 123(6):917-927. PubMed ID: 27861749
[TBL] [Abstract][Full Text] [Related]
14. A system for detecting high impact-low frequency mutations in primary tumors and metastases.
Anjanappa M; Hao Y; Simpson ER; Bhat-Nakshatri P; Nelson JB; Tersey SA; Mirmira RG; Cohen-Gadol AA; Saadatzadeh MR; Li L; Fang F; Nephew KP; Miller KD; Liu Y; Nakshatri H
Oncogene; 2018 Jan; 37(2):185-196. PubMed ID: 28892047
[TBL] [Abstract][Full Text] [Related]
15. Evolutionary Mechanisms of Cancer Suggest Rational Therapeutic Approaches.
Balzerano A; Paccosi E; Proietti-De-Santis L
Cytogenet Genome Res; 2021; 161(6-7):362-371. PubMed ID: 34461614
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.
Cannataro VL; Gaffney SG; Stender C; Zhao ZM; Philips M; Greenstein AE; Townsend JP
Oncogene; 2018 May; 37(18):2444-2455. PubMed ID: 29453361
[TBL] [Abstract][Full Text] [Related]
17. High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.
Lionetti M; Fabris S; Cutrona G; Agnelli L; Ciardullo C; Matis S; Ciceri G; Colombo M; Maura F; Mosca L; Gentile M; Recchia AG; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Rossi D; Gaidano G; Morabito F; Ferrarini M; Neri A
Br J Haematol; 2014 Jun; 165(5):629-39. PubMed ID: 24579978
[TBL] [Abstract][Full Text] [Related]
18. Targeted next-generation sequencing assays using triplet samples of normal breast tissue, primary breast cancer, and recurrent/metastatic lesions.
Akahane T; Kanomata N; Harada O; Yamashita T; Kurebayashi J; Tanimoto A; Moriya T
BMC Cancer; 2020 Oct; 20(1):944. PubMed ID: 33004031
[TBL] [Abstract][Full Text] [Related]
19. Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance.
Marusyk A; Janiszewska M; Polyak K
Cancer Cell; 2020 Apr; 37(4):471-484. PubMed ID: 32289271
[TBL] [Abstract][Full Text] [Related]
20. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.
Groisberg R; Hong DS; Roszik J; Janku F; Tsimberidou AM; Javle M; Meric-Bernstam F; Subbiah V
Mol Cancer Ther; 2018 Jul; 17(7):1595-1601. PubMed ID: 29654067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]